MarkWide Research

Sale!

Oncology Biosimilars Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: December, 2022
No of Pages: 164
Delivery Format: PDF+ Excel

$2,950.00

 

Oncology Biosimilars Market
1) Global Oncology Biosimilars Market Size, Share, Trends, Analysis and Forecast, 2019-2026
The global oncology biosimilars market is expected to grow at a CAGR of around 20% during the forecast period of 2019-2026. The major factor driving the growth of the market is the increasing prevalence of cancer. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. The number of new cancer cases is expected to rise by about 70% over the next two decades.

The other drivers of the oncology biosimilars market include the increasing number of clinical trials, the favorable regulatory landscape, and the growing number of patent expirations. However, the high cost of biosimilars and the lack of awareness among patients and physicians are the major factors restraining the growth of the market.

The oncology biosimilars market is segmented by type, application, and geography. By type, the market is divided into monoclonal antibodies (MAbs), small molecule drugs, and others. The MAbs segment is expected to grow at the highest CAGR during the forecast period. By application, the market is classified into breast cancer, colorectal cancer, lung cancer, and others. The breast cancer segment is expected to hold the largest share of the market in 2019.

Geographically, the global oncology biosimilars market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to hold the largest share of the market in 2019. The region is expected to grow at a significant CAGR during the forecast period, owing to the favorable regulatory landscape, the increasing number of clinical trials, and the growing number of patent expirations.

The key players operating in the global oncology biosimilars market are Amgen, Inc., Boehringer Ingelheim International GmbH, Pfizer Inc., Sandoz International GmbH, Samsung Bioepis Co., Ltd., and Teva Pharmaceutical Industries Ltd.

2) Oncology Biosimilars Market: Key Players
The global oncology biosimilars market is projected to grow at a CAGR of over 20% during the forecast period of 2019-2024. The major drivers for this market are the increasing prevalence of cancer and the increasing number of biosimilar approvals.

There are two key players in the oncology biosimilars market, Amgen and Pfizer.

Amgen is one of the largest independent biotechnology companies in the world. The company was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen focuses on developing therapies for serious illnesses. The company’s product portfolio includes treatments for cancer, kidney disease, rheumatoid arthritis, and psoriasis.

Pfizer is a global pharmaceutical company that was founded in 1849. The company is headquartered in New York City and has operations in over 180 countries. Pfizer’s product portfolio includes treatments for Alzheimer’s disease, cancer, heart disease, and erectile dysfunction.

The oncology biosimilars market is highly competitive and is expected to witness a high degree of consolidation in the coming years.

3) Oncology Biosimilars Market: Drivers and Challenges
The oncology biosimilars market is expected to grow in the coming years due to various factors. Some of the key drivers for this market growth include the increasing prevalence of cancer, the expiry of patents of some of the key cancer drugs, and the growing adoption of biosimilars in the oncology treatment. However, there are some challenges that need to be addressed for the successful growth of this market, such as the high cost of biosimilars, the lack of awareness about biosimilars, and the stringent regulations for the approval of biosimilars.

4) Oncology Biosimilars Market: Geographic Outlook
The oncology biosimilars market is expected to grow at a CAGR of over 35% during the forecast period. The market is segmented by geography into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America is expected to be the largest market for oncology biosimilars due to the presence of a large number of key players in the region. Moreover, the region has a large number of oncology patients, which is expected to drive the growth of the oncology biosimilars market in North America.

Europe is expected to be the second-largest market for oncology biosimilars due to the favorable reimbursement policies for biosimilars. Moreover, the presence of a large number of key players in the region is expected to drive the growth of the oncology biosimilars market in Europe.

Asia Pacific is expected to be the fastest-growing market for oncology biosimilars due to the presence of a large number of patients with cancer and the increasing awareness about biosimilars. Moreover, the governments in the region are providing financial support for the development of biosimilars, which is expected to drive the growth of the oncology biosimilars market in Asia Pacific.

The Middle East & Africa is expected to be the smallest market for oncology biosimilars due to the lack of awareness about biosimilars and the lack of reimbursement policies for biosimilars.

5) Oncology Biosimilars Market: Segmental Analysis
The oncology biosimilars market is expected to grow at a CAGR of over 20% during the forecast period. The rising prevalence of cancer and the increasing number of biosimilar approvals are the major factors driving the growth of this market.

According to the World Health Organization (WHO), the global cancer burden is expected to rise to 21.4 million new cases and 13.2 million cancer-related deaths by 2030. The number of new cancer cases is projected to increase by 70% over the next two decades. The increasing burden of cancer is one of the major factors driving the growth of the oncology biosimilars market.

The number of biosimilar approvals is also expected to increase during the forecast period. In 2018, the FDA approved four oncology biosimilars, including Zoetis’ Ziextenzo (adalimumab-adaz), Mylan’s Ogivri (trastuzumab-dkst), Pfizer’s Brenzys (etanercept-szzs), and Sandoz’s Erelzi (etanercept-szzs). The increasing number of biosimilar approvals is expected to boost the growth of the oncology biosimilars market during the forecast period.

The oncology biosimilars market has been segmented into four major segments: breast cancer, colorectal cancer, non-small cell lung cancer (NSCLC), and others.

The breast cancer segment is expected to grow at the highest CAGR during the forecast period. Breast cancer is the most common cancer among women, with an estimated 1.7 million new cases and 627,000 deaths in 2018. The high incidence of breast cancer is expected to drive the growth of the oncology biosimilars market during the forecast period.

The colorectal cancer segment is expected to grow at the second-highest CAGR during the forecast period. Colorectal cancer is the third most common cancer in both men and women, with an estimated 1.8 million new cases and 861,000 deaths in 2018. The high incidence of colorectal cancer is expected to boost the

6) Oncology Biosimilars Market: Future Outlook
The oncology biosimilars market is expected to grow significantly in the coming years. This is due to the increasing availability of biosimilar drugs, as well as the growing number of cancer patients globally.

According to a report by Grand View Research, the global oncology biosimilars market is expected to reach USD 13.4 billion by 2025. This is a significant increase from the USD 1.4 billion recorded in 2016.

The report attributes this market growth to the increasing number of cancer patients globally, as well as the expiring patents of several cancer drugs. This is leading to the increased availability of biosimilar drugs, which are cheaper alternatives to branded drugs.

In addition, the report notes that the increasing adoption of biosimilars by healthcare professionals is another key factor driving market growth. Biosimilars are now being used to treat a variety of cancers, including breast cancer, colorectal cancer, and non-small cell lung cancer.

The oncology biosimilars market is expected to continue growing at a significant pace in the coming years. This growth will be driven by the increasing availability of biosimilar drugs, as well as the growing number of cancer patients globally.

Key Players Covered

 

Some of the major companies that are present in the global oncology biosimilars market are Sandoz International GmbH, Celltrion Inc., Pfizer Inc., Amgen Inc., Samsung Bioepis, Biogen International, Merck & Co., Inc., Coherus Biosciences and other players.

 

SEGMENTATION

 

DETAILS

 

 

By Drug Class

 

 

·      mAb (monoclonal antibodies)

·      G-CSF

·      Hematopoietic Agents

·      Others

 

 

By Type of Cancer

 

 

·      Lung Cancer

·      Breast Cancer

·      Prostate Cancer

·      Stomach Cancer

·      Cervical Cancer

·      Blood Cancer

·      Brain Cancer

·      Others

 

 

By Distribution Channel

 

 

·      Hospital Pharmacies

·      Retail Pharmacies

·      Online Pharmacies

 

 

By Geography

 

 

·      North America (USA and Canada)

·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·      Latin America (Brazil, Mexico and Rest of Latin America)

·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

 

 

 

 

By Drug Class

 

 

·      mAb (monoclonal antibodies)

·      G-CSF

·      Hematopoietic Agents

·      Others

 

 

By Type of Cancer

 

 

·      Lung Cancer

·      Breast Cancer

·      Prostate Cancer

·      Stomach Cancer

·      Cervical Cancer

·      Blood Cancer

·      Brain Cancer

·      Others

 

 

By Distribution Channel

 

 

·      Hospital Pharmacies

·      Retail Pharmacies

·      Online Pharmacies

 

Some of the major companies that are present in the global oncology biosimilars market are Sandoz International GmbH, Celltrion Inc., Pfizer Inc., Amgen Inc., Samsung Bioepis, Biogen International, Merck & Co., Inc., Coherus Biosciences and other players.

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF